Tobacco Boosts In-Store Advertising

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

WASHINGTON-Tobacco companies, which were banned from touting their products on billboards last year, have increased their advertising at point-of-sale locations, such as convenience stores, according to a new study funded by the Robert Wood Johnson Foundation.

WASHINGTON—Tobacco companies, which were banned from touting their products on billboards last year, have increased their advertising at point-of-sale locations, such as convenience stores, according to a new study funded by the Robert Wood Johnson Foundation.

In-store advertising was present in 80% of the stores visited, an increase of 27% over the display ads present prior to the billboard ban. Exterior advertising was observed at 60% of the stores, an increase of 22%. Tobacco promotions were available at 52% of stores visited after the ban, an increase of 65%.

“The shift in advertising expenditure is likely to mean that any intended effect of the billboard advertising ban—as well as other advertising restrictions—will not be fully realized,” said lead researcher Frank Chaloupka, PhD, of the University of Illinois at Chicago.

Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Related Content